NCT05989204
TmCD19-IL18 in CD19+ Cancers
Active, Not Recruiting
PHASE1Ages 18+InterventionalTreatmentUniversity of PennsylvaniaInvestigator-initiated
~26 participants
Updated 2026-07-10 on ClinicalTrials.gov
What's tested:TmCD19-IL18
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of subjects with dose limiting toxicities (DLTs)
Measured over 28 days after TmCD19-IL18 CART T cell infusion
+2 more outcomes measured
Conditions
Where it's being run
1 sites across 1 statesPennsylvania1
Study leadership
- Jakub Svoboda, MD · PRINCIPAL_INVESTIGATOR · University of Pennsylvania
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Number of subjects with dose limiting toxicities (DLTs)28 days after TmCD19-IL18 CART T cell infusion
- Determination of maximum tolerated dose (MTD)28 days after TmCD19-IL18 CART T cell infusion
- Incidence of Adverse Events as assessed by CTCAE v5.0Up to 15 years